$VASO

VASO Corp

Vaso is a healthcare equipment and information technology company headquartered in Plainview, Long Island, New York. It operates through three segments. VasoTechnology provides managed network infrastructure, transport and security services. VasoHealthcare sells GE HealthCare diagnostic imaging equipment, ultrasound systems, service agreements, training and financing services to healthcare providers in assigned U.S. markets. VasoMedical designs, manufactures, sells and services proprietary medical devices and software, including Biox ambulatory monitors, ARCS analysis and reporting software, MobiCare wireless vital-sign monitors and EECP therapy systems. Vaso makes money from network services, sales and related services for GE HealthCare equipment, and the sale and servicing of its own medical products. It serves customers in the United States and China directly, and uses independent distributors mainly for international sales and service. Its healthcare IT services division was sold in November 2025.

0
0
1

No SEC Form 4 filings for $VASO in the last 30 days.

See all $VASO insider activity →
Med

Vasomedical reports Q3 results

Vasomedical reported Q3 revenue of $10.8M, down 12.9% year-over-year. Net income from continuing operations fell to $568K from $1.6M in the same period last year. Adjusted EBITDA also decreased to $691K from $1.3M. The company had $53.3M in cash and equivalents.

Vaso Stock Surges 149% in a Year: What's Behind the Rally?

Vaso Corporation's stock surged 149% in the past year, outperforming industry peers and the S&P 500. The company reported higher revenues and profitability in Q2 2026, driven by growth in professional sales services and equipment segments. Recent developments include the sale of NetWolves and a focus on healthcare businesses. Vaso's valuation remains below industry average but above its historical median.

VASO Corp (VASO): Completion of Acquisition or Disposition of Assets

VASO Corp (VASO) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 1.01. Entry into a Material Definitive Agreement. On July 31, 2026, Vaso Corporation (“Vaso”), VasoTechnology, Inc., a Delaware corporation and wholly owned subsidiary of Vaso (“VasoTech”), NetWolves Network Services LLC, a Florida limited liability company and wholly owned

VASO sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning VASO (VASO Corp). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.

Recent VASO coverage spans financial news, earnings and mergers & acquisitions.

What's driving VASO

  • Q3 results show year-over-year revenue and adjusted EBITDA declines, which can pressure near-term sentiment and valuation until guidance or cost actions offset weakness.

    seekingalpha.com · Nov 16, 2026

  • Momentum appears supported by improving fundamentals and a simplified portfolio, but the stock’s outlook remains sensitive to GE HealthCare delivery continuity and VasoMedical margin pressure.

    zacks.com · Oct 16, 2026

  • Deal closing is a concrete corporate event that can change VASO’s asset base, cash flows, and risk profile, but the excerpt lacks deal size and financial impact.

    SEC EDGAR 8-K · Jul 31, 2026

  • Board and audit-committee composition changes may modestly affect governance and oversight expectations, but no operational or financial guidance is provided.

    SEC EDGAR 8-K · Jul 23, 2026

  • VASO reported record revenue in Q1 2025 with a narrowed net loss, yet the stock declined post-earnings. This suggests investor caution or profit-taking despite solid financial performance.

    Zacks Commentary · May 20, 2025

AlphAI scores every news story that mentions VASO with an AI model for sentiment and relevance, and aggregates insider trades from VASO Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $VASO

Score

Vasomedical reports Q3 results

Vasomedical reported Q3 revenue of $10.8M, down 12.9% year-over-year. Net income from continuing operations fell to $568K from $1.6M in the same period last year. Adjusted EBITDA also decreased to $691K from $1.3M. The company had $53.3M in cash and equivalents.

Vaso Stock Surges 149% in a Year: What's Behind the Rally?

Vaso Corporation's stock surged 149% in the past year, outperforming industry peers and the S&P 500. The company reported higher revenues and profitability in Q2 2026, driven by growth in professional sales services and equipment segments. Recent developments include the sale of NetWolves and a focus on healthcare businesses. Vaso's valuation remains below industry average but above its historical median.

$VASOMedM&A· $14.5M · completed

VASO Corp (VASO): Completion of Acquisition or Disposition of Assets

VASO Corp (VASO) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 1.01. Entry into a Material Definitive Agreement. On July 31, 2026, Vaso Corporation (“Vaso”), VasoTechnology, Inc., a Delaware corporation and wholly owned subsidiary of Vaso (“VasoTech”), NetWolves Network Services LLC, a Florida limited liability company and wholly owned

$VASOLowExec change· appointed

VASO Corp (VASO): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

VASO Corp (VASO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0000839087 0000839087 2026-07-23 2026-07-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report

Related tickers